NO20002697L - Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen - Google Patents
Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-genInfo
- Publication number
- NO20002697L NO20002697L NO20002697A NO20002697A NO20002697L NO 20002697 L NO20002697 L NO 20002697L NO 20002697 A NO20002697 A NO 20002697A NO 20002697 A NO20002697 A NO 20002697A NO 20002697 L NO20002697 L NO 20002697L
- Authority
- NO
- Norway
- Prior art keywords
- diagnostic
- variation
- diseases caused
- therapeutic preparation
- lkb1 gene
- Prior art date
Links
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34425697 | 1997-11-27 | ||
| JP28035798 | 1998-10-01 | ||
| PCT/JP1998/005357 WO1999028459A1 (fr) | 1997-11-27 | 1998-11-27 | Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002697D0 NO20002697D0 (no) | 2000-05-26 |
| NO20002697L true NO20002697L (no) | 2000-07-27 |
Family
ID=26553739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002697A NO20002697L (no) | 1997-11-27 | 2000-05-26 | Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6800436B1 (fr) |
| EP (1) | EP1036844A4 (fr) |
| AU (1) | AU750564B2 (fr) |
| CA (1) | CA2311414A1 (fr) |
| NO (1) | NO20002697L (fr) |
| WO (1) | WO1999028459A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1186232A4 (fr) | 1999-05-31 | 2004-11-10 | Chugai Pharmaceutical Co Ltd | Animaux rompant le gene lkb1 |
| AU2001271067A1 (en) * | 2000-07-19 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound |
| DK1633883T3 (da) * | 2003-06-17 | 2009-01-26 | Medical Res Council | Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet |
| AU2005314335C1 (en) * | 2004-12-08 | 2012-08-16 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
| CA2611788A1 (fr) * | 2005-06-30 | 2007-01-11 | Syngenta Participations Ag | Procedes de criblage de polymorphismes d'hybridation specifiques de gene (gshp) et leur utilisation dans la cartographie genetique et le developpement d'un marqueur |
| EP2992878A1 (fr) * | 2010-02-03 | 2016-03-09 | Signal Pharmaceuticals, LLC | Identification d'une mutation lkb1 comme biomarqueur prédictif de la sensibilité aux inhibiteurs de la kinase tor |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| HK1221150A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪类对癌症的治疗 |
| HK1221174A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法 |
| MX364101B (es) | 2013-04-17 | 2019-04-12 | Signal Pharm Llc | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. |
| SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| CA2909579A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Therapie combinee comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide pour le traitement d'un cancer |
| EA030808B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ |
| WO2014172432A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer |
| CA3143529A1 (fr) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl) -l-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(lh) -one, forme solide de celle-ci et p rocedes pour les |
| WO2015160880A1 (fr) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5709999A (en) * | 1994-08-12 | 1998-01-20 | Myriad Genetics Inc. | Linked breast and ovarian cancer susceptibility gene |
| JPH08308586A (ja) * | 1995-03-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | プロテインキナーゼをコードするｄｎａ |
| US5827726A (en) | 1995-03-16 | 1998-10-27 | Chugai Seiyaku Kabushiki Kaisha | DNA coding protein kinase |
-
1998
- 1998-11-27 AU AU12620/99A patent/AU750564B2/en not_active Ceased
- 1998-11-27 US US09/555,166 patent/US6800436B1/en not_active Expired - Fee Related
- 1998-11-27 WO PCT/JP1998/005357 patent/WO1999028459A1/fr not_active Ceased
- 1998-11-27 CA CA002311414A patent/CA2311414A1/fr not_active Abandoned
- 1998-11-27 EP EP98955971A patent/EP1036844A4/fr not_active Withdrawn
-
2000
- 2000-05-26 NO NO20002697A patent/NO20002697L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2311414A1 (fr) | 1999-06-10 |
| AU750564B2 (en) | 2002-07-25 |
| AU1262099A (en) | 1999-06-16 |
| NO20002697D0 (no) | 2000-05-26 |
| WO1999028459A1 (fr) | 1999-06-10 |
| EP1036844A4 (fr) | 2002-12-04 |
| US6800436B1 (en) | 2004-10-05 |
| EP1036844A1 (fr) | 2000-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002697L (no) | Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen | |
| ATE464050T1 (de) | Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung | |
| NO20016364D0 (no) | Fremgangsmåte og anordning for noninvasiv blodanalysemåling | |
| NO20012689D0 (no) | Nye fluider og teknikker for matriks syrebehandling | |
| FI963101L (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
| NO20003288L (no) | Preparat for behandling av respiratoriske sykdommer og hudsykdommer, omfattende minst en leukotrienantagonist og minst ett antihistamin | |
| DE69632143D1 (de) | Ball und methode zu seiner herstellung | |
| DE60336264D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung | |
| DE69901177D1 (de) | Platinkomplex, dessen herstellung und dessen therapeutische verwendung | |
| ATE267202T1 (de) | 1,4-diazabicyclo(3.2.2)nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| NO961000D0 (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike | |
| AU7041400A (en) | Health care system and method thereof | |
| AU6939700A (en) | System and method for genomic and proteomic human disease assessment via expression profile comparison | |
| AU6225999A (en) | Disposable training pant, apparatus and method for manufacturing it | |
| AU2002239664A1 (en) | Method for drug development using individual patient response | |
| WO2002063951A3 (fr) | Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique | |
| AU2002332102A1 (en) | System, method, and apparatus for disease susceptibility testing | |
| DE60003662D1 (de) | Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| AU2003276727A1 (en) | Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes | |
| AU2003284166A1 (en) | Methods for diagnosing and treating pre-term labor | |
| ATE218558T1 (de) | 4-(1-piperazinyl)benzosäurederivate, verfahren zu ihrer herstellung und ihre therapeutischen verwendungen | |
| DE59911949D1 (de) | Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament | |
| DE69516534D1 (de) | Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung | |
| EP1412754A4 (fr) | Procede et agents diagnostiques | |
| AU2002238869A1 (en) | Sophisticated medical apparatus rental calculation method, program thereof, sophisticated medical apparatus introduction support system, and sophisticated medical apparatus introduction support method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |